Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Ph...
April 21 2020 - 4:05PM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women's health and prostate cancer, today
announced it will hold a webcast and conference call beginning at
8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Wednesday, April
22, 2020, to discuss results from the Phase 3 SPIRIT 2 study of
once-daily relugolix combination therapy (relugolix 40 mg plus
estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with
pain associated with endometriosis. The company will also discuss
results from a separate ovulation inhibition study with relugolix
combination therapy.
Webcast/Teleconference Details To
participate in the live conference call, please dial 1-800-532-3746
for domestic callers and +1-470-495-9166 for international
callers. A live webcast of the conference call will also be
available on the investor relations page of Myovant’s website at
investors.myovant.com and will remain archived on Myovant’s website
for at least 30 days.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on redefining care for women’s health and prostate cancer. The
company’s lead product candidate is relugolix, a once-daily, oral
GnRH receptor antagonist. The company has three late-stage
clinical programs for relugolix in uterine fibroids, endometriosis,
and prostate cancer. The company is also developing MVT-602, an
oligopeptide kisspeptin-1 receptor agonist, that has completed a
Phase 2a study for the treatment of female infertility as part of
assisted reproduction. Takeda Pharmaceuticals International AG, a
subsidiary of Takeda Pharmaceutical Company Limited, the originator
of relugolix, previously granted the company a worldwide
license to develop and commercialize relugolix (excluding Japan and
certain other Asian countries) and an exclusive license to develop
and commercialize MVT-602 in all countries worldwide. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon
Pharma Co., Ltd., is the majority shareholder of Myovant. For more
information, please visit the company’s website
at www.myovant.com. Follow @Myovant on Twitter and
LinkedIn.
Investor Contact: Frank Karbe President, Chief
Financial Officer Myovant Sciences, Inc. investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.
media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Sep 2023 to Sep 2024